Drug Therapy

Donald G. Vidt, MD
Consultant, Department of Nephrology and Hypertension, Cleveland Clinic; member, Sixth Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure; investigator, Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT)

Address: Donald G. Vidt, MD, Department of Nephrology and Hypertension, A101,  Cleveland Clinic, 9500 Euclid Avenue, Cleveland, OH 44195

Dr. Vidt has indicated that he has received grant or research support from the Searle, Astra-Zeneca, and Novartis companies and serves on the speakers' bureaus of the Astra-Zeneca, Merck, Novartis, and Solvay companies, all of which make antihypertensive agents.

Donald G. Vidt, MD
Consultant, Department of Nephrology and Hypertension, Cleveland Clinic; member, Sixth Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure; investigator, Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT)

Address: Donald G. Vidt, MD, Department of Nephrology and Hypertension, A101,  Cleveland Clinic, 9500 Euclid Avenue, Cleveland, OH 44195

Dr. Vidt has indicated that he has received grant or research support from the Searle, Astra-Zeneca, and Novartis companies and serves on the speakers' bureaus of the Astra-Zeneca, Merck, Novartis, and Solvay companies, all of which make antihypertensive agents.

Donald G. Vidt, MD
Consultant, Department of Nephrology and Hypertension, Cleveland Clinic; member, Sixth Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure; investigator, Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT)

Address: Donald G. Vidt, MD, Department of Nephrology and Hypertension, A101,  Cleveland Clinic, 9500 Euclid Avenue, Cleveland, OH 44195

Dr. Vidt has indicated that he has received grant or research support from the Searle, Astra-Zeneca, and Novartis companies and serves on the speakers' bureaus of the Astra-Zeneca, Merck, Novartis, and Solvay companies, all of which make antihypertensive agents.

S. Sethu K. Reddy, MD
Department of Endocrinology, Cleveland Clinic

Address: S. Sethu K. Reddy, MD, Department of Endocrinology, A30, Cleveland Clinic, 9500 Euclid Avenue, Cleveland, OH 44195

Dr. Reddy has indicated that he serves on the speakers' bureaus of the Parke-Davis, SmithKline Beecham, Eli Lilly, Takeda, Bristol-Myers Squibb, Aventis, Pfizer, Novo-Nordisk, and Schering companies, all of which make products for diabetes care.

S. Sethu K. Reddy, MD
Department of Endocrinology, Cleveland Clinic

Address: S. Sethu K. Reddy, MD, Department of Endocrinology, A30, Cleveland Clinic, 9500 Euclid Avenue, Cleveland, OH 44195

Dr. Reddy has indicated that he serves on the speakers' bureaus of the Parke-Davis, SmithKline Beecham, Eli Lilly, Takeda, Bristol-Myers Squibb, Aventis, Pfizer, Novo-Nordisk, and Schering companies, all of which make products for diabetes care.

S. Sethu K. Reddy, MD
Department of Endocrinology, Cleveland Clinic

Address: S. Sethu K. Reddy, MD, Department of Endocrinology, A30, Cleveland Clinic, 9500 Euclid Avenue, Cleveland, OH 44195

Dr. Reddy has indicated that he serves on the speakers' bureaus of the Parke-Davis, SmithKline Beecham, Eli Lilly, Takeda, Bristol-Myers Squibb, Aventis, Pfizer, Novo-Nordisk, and Schering companies, all of which make products for diabetes care.

Lily C. Pien, MD
Department of Allergy and Immunology, Cleveland Clinic

Address: Lily C. Pien, MD, Department of Allergy and Immunology, A72, Cleveland Clinic, 9500 Euclid Avenue, Cleveland, OH 44195; [email protected]

Lily C. Pien, MD
Department of Allergy and Immunology, Cleveland Clinic

Address: Lily C. Pien, MD, Department of Allergy and Immunology, A72, Cleveland Clinic, 9500 Euclid Avenue, Cleveland, OH 44195; [email protected]

Lily C. Pien, MD
Department of Allergy and Immunology, Cleveland Clinic

Address: Lily C. Pien, MD, Department of Allergy and Immunology, A72, Cleveland Clinic, 9500 Euclid Avenue, Cleveland, OH 44195; [email protected]

Thomas F. Keys, MD
Department of Infectious Disease, Cleveland Clinic

Thomas F. Keys, MD
Department of Infectious Disease, Cleveland Clinic

Thomas F. Keys, MD
Department of Infectious Disease, Cleveland Clinic

Leonard H. Calabrese, DO
R.J. Fasenmyer Chair of Clinical Immunology, Department of Rheumatic and Immunologic Diseases, Cleveland Clinic

Address: Leonard H. Calabres,e DO, Department of Rheumatic and Immunologic Diseases, A50, Cleveland Clinic, 9500 Euclid Avenue, Cleveland, Ohio 44195; [email protected]

Leonard H. Calabrese, DO
R.J. Fasenmyer Chair of Clinical Immunology, Department of Rheumatic and Immunologic Diseases, Cleveland Clinic

Address: Leonard H. Calabres,e DO, Department of Rheumatic and Immunologic Diseases, A50, Cleveland Clinic, 9500 Euclid Avenue, Cleveland, Ohio 44195; [email protected]

Leonard H. Calabrese, DO
R.J. Fasenmyer Chair of Clinical Immunology, Department of Rheumatic and Immunologic Diseases, Cleveland Clinic

Address: Leonard H. Calabres,e DO, Department of Rheumatic and Immunologic Diseases, A50, Cleveland Clinic, 9500 Euclid Avenue, Cleveland, Ohio 44195; [email protected]

Byron J. Hoogwerf, MD
Department of Endocrinology, Director, Internal Medicine Residency Program, Cleveland Clinic; investigator, Heart Outcomes Prevention Evaluation (HOPE) study

James B. Young, MD
Head, Section of Heart Failure and Cardiac Transplant Medicine, Department of Cardiology, Cleveland Clinic; member, steering committee, Heart Outcomes Prevention Evaluation (HOPE) study

Address: Byron J. Hoogwerf, MD, Department of Endocrinology, A30, Cleveland Clinic, 9500 Euclid Avenue, Cleveland, OH 44195; [email protected]

This paper discusses off-label uses of medication. The HOPE study was funded by the Medical Research Council of Canada, Hoechst-Marion Roussel, AstraZeneca, King Pharmacuticals, Natural Source Vitamin E Association, Negma, and the Heart and Stroke Foundation of Ontario.

Drs. Hoogwerf and Young serve as consultants for Monarch Pharmaceuticals.

Byron J. Hoogwerf, MD
Department of Endocrinology, Director, Internal Medicine Residency Program, Cleveland Clinic; investigator, Heart Outcomes Prevention Evaluation (HOPE) study

James B. Young, MD
Head, Section of Heart Failure and Cardiac Transplant Medicine, Department of Cardiology, Cleveland Clinic; member, steering committee, Heart Outcomes Prevention Evaluation (HOPE) study

Address: Byron J. Hoogwerf, MD, Department of Endocrinology, A30, Cleveland Clinic, 9500 Euclid Avenue, Cleveland, OH 44195; [email protected]

This paper discusses off-label uses of medication. The HOPE study was funded by the Medical Research Council of Canada, Hoechst-Marion Roussel, AstraZeneca, King Pharmacuticals, Natural Source Vitamin E Association, Negma, and the Heart and Stroke Foundation of Ontario.

Drs. Hoogwerf and Young serve as consultants for Monarch Pharmaceuticals.

Byron J. Hoogwerf, MD
Department of Endocrinology, Director, Internal Medicine Residency Program, Cleveland Clinic; investigator, Heart Outcomes Prevention Evaluation (HOPE) study

James B. Young, MD
Head, Section of Heart Failure and Cardiac Transplant Medicine, Department of Cardiology, Cleveland Clinic; member, steering committee, Heart Outcomes Prevention Evaluation (HOPE) study

Address: Byron J. Hoogwerf, MD, Department of Endocrinology, A30, Cleveland Clinic, 9500 Euclid Avenue, Cleveland, OH 44195; [email protected]

This paper discusses off-label uses of medication. The HOPE study was funded by the Medical Research Council of Canada, Hoechst-Marion Roussel, AstraZeneca, King Pharmacuticals, Natural Source Vitamin E Association, Negma, and the Heart and Stroke Foundation of Ontario.

Drs. Hoogwerf and Young serve as consultants for Monarch Pharmaceuticals.